ABOUT THE EVENT
Date: Wednesday, September 10, 2025 8am PDT
Event Location: Virtual
Neuromuscular blocking agents (NMBAs) are essential for surgical procedures and airway management—but they’re not without risks. Rocuronium, one of the most commonly used nondepolarizing NMBAs, is also associated with severe adverse effects like prolonged neuromuscular blockade and, more rarely, anaphylaxis.
In this session, Professor Pierre Bruhns from Institut Pasteur will present new insights into the antibody responses of patients with suspected hypersensitivity to rocuronium. His team has identified drug-specific memory B cell repertoires that help explain how certain immune responses are triggered—and how they might be harnessed for improved diagnostics or therapeutic development.
Topics covered will include:
Identification of antibodies with high specificity for rocuronium
Functional characterization of IgE antibodies in triggering allergic responses
Potential use of high-affinity antibodies to reverse neuromuscular blockade in preclinical models
This webinar will be of particular interest to researchers and clinicians working in immunology, allergy, and drug safety.
About the Speaker
Pr Bruhns leads the Antibodies in Therapy and Pathology lab at Institut Pasteur, focusing on antibody function in health and disease. He is an internationally recognized expert in Fc receptor biology, in vivo disease models, and droplet microfluidics applied to immune responses. As a European Research Council (ERC) grantee, he has led pioneering projects in immunology and antibody therapeutics. He has published over 130 articles and reviews, holds five patents (three licensed), and regularly organizes international conferences.
